PQDx 0033-013-00 WHO
PQ Public Report
July/2016, version 5.0
PQDx 0159-055-00
WHO PQ Public Report
February/2017, version 5.0
8th IAS Conference on HIV Pathogenesis 19-22 July 2015 Vancouver
Anita Sands Prequalification Team – Diagnostics Essential Medicines and Health Product
Ade et al. BMC Health Services Research (2016) 16:5
Background: In the “Centre National Hospitalier de Pneumo-Phtisiologie” of Cotonou, Benin, little is known about
the characteristics of patients who have not attended their scheduled appointment, the results of tracing and the
possible b...enefits on improving treatment outcomes. This study aimed to determine the contribution of tracing
activities for those who missed scheduled appointments towards a successful treatment outcome.
Methods: A retrospective cohort study was carried out among all smear-positive pulmonary tuberculosis patients
treated between January and September 2013. Data on demographic and diagnostic characteristics and treatment
outcomes were accessed from tuberculosis registers and treatment cards. Information on those who missed their
scheduled appointments was collected from the tracing tuberculosis register. A univariate analysis was performed
to explore factors associated with missing a scheduled appointment
more
30 April 2020
| COVID-19: Essential health services
The following protocol has been designed to investigate the First Few X cases (FFX) and their close contacts. It is envisioned that the FFX 2019-nCoV investigation will be conducted across several countries or sites with geographical and demographical diversity. Using a standardized protocol such a...s the protocol provided here, epidemiological exposure data and biological samples can be systematically collected and shared rapidly in a format that can be easily aggregated, tabulated and analyzed across many different settings globally for timely estimates of 2019-nCoV infection severity and transmissibility, as well as to inform public health responses and policy decisions. This is particularly important in the context of a novel respiratory pathogen, such as 2019-nCoV
more
This document is intended for use by state and local health departments and healthcare facilities and serves as general guidance for the initial response for the containment of novel or targeted multidrug-resistant organisms (MDROs) or resistance mechanisms. It is not intended to describe all the ac...tions that might be required for control of an outbreak (e.g., sustained transmission within a facility or region). In addition, further evaluation might be required based on the findings of the initial response described in this document.
more
It is intended for clinicians who are working in intensive care units (ICUs) in low and middle-income countries and managing adult and pediatric patients with severe forms of acute respiratory infection (SARI), including severe pneumonia, acute respiratory distress syndrome (ARDS), sepsis and septic... shock. It is a hands-on practical guide to be used by health care professionals involved in clinical care management during outbreaks of influenza virus (seasonal) human infection due avian influenza virus (H5N1, H7N9), MERS-CoV, COVID-19 or other emerging respiratory viral epidemics.
This course is also available in the following languages:
français - русский - Português - Bahasa Indonesia - Tiếng Việt - Español - македонски - العربية - Tetun
more
Molecular methods for antimicrobial resistance (AMR)diagnostics to enhance the Global Antimicrobial Resistance Surveillance System
On the 31st December 2019, the World Health Organization (WHO) China country office reported a cluster of pneumonia cases in Wuhan City, Hubei Province of China now known to be caused by a novel virus. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been confirmed as the causative v...irus of Coronavirus disease 2019 (COVID-19). Cases have now been identified in over 100 countries including South Africa.
more
1. What is COVID-19?
2. Who is at most risk for COVID-19?
3. What is the risk of COVID-19 infection in humans in South Africa?
4. How is COVID-19 transmitted?
5. What are the signs and symptoms of COVID-19 infection in humans?
6. How is COVID-19 diagnosed?
7. How is COVID-19 infection ...treated?
8. How can COVID-19 infection in humans be prevented?
9. What measures have been put in place in South Africa to minimise the risk of transmission should cases be imported?
10. Should I travel now?
11. Who can I contact for more information?
more
(7th Version)
20, March 2020
Временное руководство
19 марта 2020 г.
Данный документ предоставляет временное руководство лабораториям и заинтересованным сторонам, участвующим в лабораторном ...естировании пациентов с вирусом COVID-19.
Документ частично основан на временном руководстве по лабораторному тестированию на коронавирус, вызывающий ближневосточный респираторный синдром (MERS).1-6 Информация о заражении человека вирусом COVID-19 постоянно обновляется, ВОЗ продолжает следить за развитием событий и по необходимости пересматривать рекомендации.
more
Intensive Care Med (2009) 35:9–29DOI 10.1007/s00134-008-1336-9
Although thousands of papers have been devoted tohospital-acquired pneumonia (HAP), many controversiesremain, and management of HAP is probably often sub-optimal. Several reviews or guidelines have been pub-lished rec...ently, mostly by North American initiatives(CDC, ATS). Three European Societies (ERS, ESCMID andESICM) were interested in producing a document thatcould complement in some way the last IDSA/ATS guidelines published 3 years ago. In addition, the Helics
working group supported this initiative.
more
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more
The global emergence of antimicrobial resistance (AMR) is posing a threat to human health. Putting resources into the containment of AMR – including surveillance – is one of the highest-yield investments a country can make to mitigate its impact. In 2015, WHO launched the Global Antimicrobial Re...sistance Surveillance System (GLASS), the first global collaborative effort to foster AMR surveillance in bacteria causing acute infections. As of December 2018, 71 countries are enrolled in GLASS. The aim of this report is to document participation efforts and outcomes across these countries, and highlight differences and constraints identified to date. This report follows on from the first GLASS Report – Early implementation 2016-17, published in January 2018, and drawing on data from GLASS first data call in 2017.
more
Primary Care Guide for the Adult· 2020
Western Cape Edition
20 March 2020